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We have designed a PEGylated LPD (liposome- polycation-
DNA) nanoparticle for systemic, specific, and efficient 
delivery of small interfering RNA (siRNA) into solid 
tumors in mice by modification with NGR (aspargine–
glycine–arginine) peptide, targeting aminopeptidase N 
(CD13) expressed in the tumor cells or tumor vascular 
endothelium. LPD-PEG-NGR efficiently delivered siRNA 
to the cytoplasm and downregulated the target gene in 
the HT-1080 cells but not CD13− HT-29 cells, whereas 
nanoparticles containing a control peptide, LPD-PEG-
ARA, showed only little siRNA uptake and gene silencing 
activity. LPD-PEG-NGR efficiently delivered siRNA into 
the cytoplasm of HT-1080 xenograft tumor 4 hours after 
intravenous injection. Three daily injections (1.2 mg/kg) 
of c-myc siRNA formulated in the LPD-PEG-NGR effec-
tively suppressed c-myc expression and triggered cellu-
lar apoptosis in the tumor, resulting in a partial tumor 
growth inhibition. When doxorubicin (DOX) and siRNA 
were co-formulated in LPD-PEG-NGR, an enhanced ther-
apeutic effect was observed.
Received 21 July 2009; accepted 17 November 2009; published online 
12 January 2010. doi:10.1038/mt.2009.291
IntroductIon
c-myc oncogene is overexpressed and activated in various human 
tumors. It promotes cell growth, transformation, and angiogen-
esis that play important roles in the progression and metastasis of 
tumor.1 Downregulation of c-myc with antisense oligonucleotides 
inhibits tumor growth both in vitro and in vivo and sensitizes can-
cer cells to chemotherapy,2,3 possibly by induction of p53 and inhi-
bition of Bcl-2 proteins that trigger cell apoptosis.3
Surgical resection is a common primary cancer treatment. 
Radiation and chemotherapeutic agents such as doxorubicin 
(DOX) may improve treatment response and survival. However, 
resistance to chemotherapy and radiation often occurs and leads 
to poor prognosis. Delivery of small interfering RNA (siRNA) 
against an oncogene or a drug-resistant gene is a new strategy to 
increase the therapeutic armament.4–6 DOX, one of the most effec-
tive anticancer agents, is efficacious against various neoplasms 
such as acute lymphoblastic and myeloblastic leukemia, malig-
nant lymphoma, soft tissue and bone sarcoma, breast, ovarian, 
prostate, bladder, gastric, and bronchogenic carcinoma.7 However, 
the associated cardiotoxicity caused by free radicals generated by 
DOX has prompted the development of a targeted delivery vehicle 
to tumor cells.8
We have successfully developed a core/shell type of nanoparticle 
formulation, called liposome-polycation-DNA complex (LPD), to 
specifically deliver siRNA to tumor cells in vivo.9–11 DOX contains 
flat aromatic rings that intercalate into the DNA strands.12 Because 
dsDNA is a component of the LPD nanoparticle, we have decided 
to use the DNA as a carrier for DOX. We hypothesized that DOX 
may form a physical complex with the DNA inside the nanoparticles 
through noncovalent intercalation, which does not change the prop-
erty of DOX or siRNA in the LPD nanoparticles. This novel system 
may provide a platform for efficient and specific co-delivery of siRNA 
and the DNA-binding chemotherapy drug for cancer treatment.
In this study, we have designed the LPD nanoparticles armed 
with NGR, a peptide motif targeting CD13 (ref. 13) which is 
upregulated in angiogenic tumor vasculature and various cancer 
cells such as HT-1080 human fibrosarcoma cells. CD13 is a multi-
functional protein involved in cancer angiogenesis, invasion, and 
metastasis.14 NGR-containing peptides have been successfully used 
to deliver cytotoxic drugs such as DOX, apoptotic peptides, and 
cytokines such as tumor necrosis factor to the tumor or tumor vas-
culature, and enhance the antitumor activity of the cargo.13,15–20
In the present study, we have developed LPD nanoparticles mod-
ified with PEGylated NGR for targeted co-delivery of siRNA and 
DOX in vitro and in vivo. We have shown increasing cellular uptake 
of siRNA, profound downregulation of the target gene, enhanced 
apoptosis of the tumor cells and improved tumor growth inhibition 
effect triggered by LPD-PEG-NGR containing c-myc siRNA. These 
results indicate that the suppression of c-myc protein by NGR-
targeted siRNA therapy and the co-delivery of c-myc siRNA and 
DOX could provide an efficient strategy for cancer treatment.
results
uptake of sirnA in vitro
The average size of the LPD-PEG-NGR nanoparticles was 
197 ± 1 nm, and the zeta potential was 30.5 ± 0.6 mV. As shown 
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in Figure 1b, the uptake of fluorescently labeled siRNA was 
much greater in HT-1080 cells treated with LPD-PEG-NGR 
than cells treated with LPD-PEG-ARA. It indicates that NGR 
ligand increased the delivery efficiency of the nanoparticles 
for CD13 expressing cells, HT-1080. The CD13− cell line 
HT-29 (Figure 1b) did not show fluorescence, suggesting that 
uptake of siRNA is related to CD13 expression. To test the 
specificity of NGR-mediated uptake, competitive inhibition 
was performed with excess free NGR or ARA peptides. The 
presence of NGR, but not ARA, peptides reduces the siRNA 
uptake of HT-1080 cells treated with LPD-PEG-NGR (see 
Supplementary Materials and Supplementary Figure S1). 
Supplementary Figure S2 indicates that LPD-PEG-NGR can 
also efficiently deliver siRNA into HUVEC (human umbilical 
vein endothelial cells).
c-myc gene silencing in vitro
To further demonstrate the biological activity of the formulation, 
siRNA against human c-myc was delivered by either LPD-PEG-
NGR or LPD-PEG-ARA. Its effect on c-myc levels was deter-
mined by quantitative RT-PCR (see Supplementary Materials 
and Methods), immunostaining, and western blot analysis 
(Figure 1c–e and Supplementary Figure S3). The c-myc mRNA 
and protein expression of HT-1080 cells treated with c-myc 
siRNA-containing LPD-PEG-NGR was significantly inhibited 
(Figure 1c,e and Supplementary Figure S3). However, anti-c-
myc siRNA-containing LPD-PEG-ARA could only slightly down-
regulate c-myc. The CD13− cell line HT-29 (Figure 1d,e) did not 
show silencing activity. The data indicate that siRNA could effec-
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Figure 1 Intracellular uptake of sirnA and c-myc expression inhibited by sirnA formulation in vitro. (a) The structure of DSPE-PEG-NGR. 
(b) Fluorescence photographs of HT-1080 and HT-29 cells after treatment with 5′-Cy3-labeled siRNA against an irrelevant target in LPD-PEG-NGR 
and LPD-PEG-ARA for 4 hours. Western blot analysis of c-myc and β-actin in (c) HT-1080 cells and (d) HT-29 after treatment with 250 nmol/l siRNA 
in different formulations for 24 hours. (e) Immunocytochemical staining of c-myc after treatment with 250 nmol/l siRNA in different formulations for 
24 hours.
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uptake of sirnA in vivo
We studied the cy3-siRNA uptake of HT-1080 tumor tissue in 
the tumor-bearing mice 4 hours after IV injections using confo-
cal microscopy. As shown in Figure 2a, the intracellular fluores-
cence signals were hardly detected in the tumor tissues collected 
from the mice treated with LPD-PEG-ARA. The LPD-PEG-NGR 
showed strong cytosolic delivery of cy3-siRNA in the tumor tissue. 
The distribution of cy3-siRNA in the tumor was heterogeneous. 
These results indicate that the LPD-PEG-NGR can efficiently 
deliver siRNA to the tumor tissue and the intracellular delivery 
is targeting peptide dependent. In other organs (Figure 2b), the 
liver and the kidney showed stronger uptake of free siRNA than 
siRNA formulated in the targeted nanoparticles, whereas the tar-
geted nanoparticles showed stronger siRNA delivery in the tumor 
tissue than free siRNA. The uptake of siRNA formulated in the 
targeted nanoparticles was under the detection limit in the heart, 
the spleen, and the lung.
c-myc gene silencing and apoptosis induction
To examine the biological activities of siRNA in vivo, c-myc 
level in the tumor was assayed by western blot analysis and 
immunostaining (Figure 3a,b). c-myc expression in HT-1080 
tumor was silenced by siRNA delivered with LPD-PEG-NGR. 
The LPD-PEG-ARA showed only a partial effect, whereas the 
control siRNA showed no effect. We also stained for the apop-
totic markers in the HT-1080 tumor (Figure 3c). Figure 3c,d 
indicate that about 5% of HT-1080 cells treated with c-myc 
siRNA containing LPD-PEG-NGR underwent apoptosis as 
detected by the TUNEL staining. This value was significantly 
higher than the ones treated with c-myc siRNA formulated in 
LPD-PEG-ARA, or control siRNA formulated in either LPD-
PEG-NGR or LPD-PEG-ARA. The results indicate that c-myc 











































Figure 2 tumor uptake of sirnA in different formulations. 
(a) Fluorescence signal of cy3-labeled siRNA in HT-1080 tumor observed 
by confocal microscopy. (b) Tissue distribution of FITC-siRNA in different 
formulations. Data = mean ± SD, n = 3. *P < 0.05 compared with free 
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Figure 3 c-myc expression and apoptosis induction in Ht-1080 xenograft tumor. (a) Western blot analysis of c-myc in the HT-1080 xenograft tumor 
after treatment with different formulations. (b) c-myc expression and (c) TUNEL staining in HT-1080 tumor cells after treated with siRNA with different 
formulation in vivo. (d) Quantitative analysis of TUNEL positive staining in the tumors treated with different formulations. N = 3~5. **P < 0.001.
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in the HT-1080 tumor and the apoptosis effect was targeting 
peptide dependent.
tumor growth inhibition by sirnA nanoparticles
Three injections of c-myc siRNA in LPD-PEG-NGR showed a 
partial inhibition of tumor growth (P < 0.05 at day 21) (Figure 4). 
Other control groups treated with c-myc siRNA formulated 
in LPD-PEG-ARA, control siRNA formulated in LPD-PEG-
NGR had no therapeutic effect. The results indicate that c-myc 
siRNA formulated with LPD-PEG-NGR can inhibit the growth 
of HT-1080 tumor and the tumor growth inhibition effect was 
targeting peptide dependent. The LPD-PEG-NGR nanoparticles 
efficiently delivered siRNA to the solid tumor and almost totally 
silenced the target gene, c-myc, throughout the entire HT-1080 
tumor. Because only partial apoptosis and growth inhibition of 
the tumor was observed, we hypothesized that it was due to the 
existence of alternative mechanisms of proliferation or some anti-
apoptosis events in the tumor. To enhance the therapeutic activity 
of LPD-PEG-NGR nanoparticles containing c-myc siRNA, we co-
delivered siRNA and DOX to the tumor cells. DOX has a unique 
property to bind with dsDNA by base intercalation.12 Because 
dsDNA is a component of the LPD nanoparticles, we have decided 
to use DNA as a carrier for DOX. We hypothesized that DOX will 
form a physical complex with DNA inside the LPD nanoparticles 
by noncovalent intercalation, which will not change the property 
























Figure 4 Ht-1080 xenograft tumor growth inhibition by sirnA in dif-
ferent formulations. Solid arrows indicate the intravenous administra-
tions of siRNA (1.2 mg/kg). Data = mean, n = 5–7. SD of the data points 
is not shown for clarity. *P < 0.05. PBS, phosphate-buffered saline.


























































































Figure 5 Intracellular uptake of doX in vitro. (a) Illustration of preparation of LPD-PEG-NGR containing siRNA and DOX. (b) Fluorescence pho-
tographs of HT-1080 and HT-29 cells after treatment with DOX in LPD-PEG-NGR (NGR), LPD-PEG-ARA (ARA), and LPD-PEG (PEG) for 1 hour. 
(c) Quantitative measurement of DOX uptake in HT-1080 cells by flow cytometry. (d) Uptake of siRNA and DOX by HT-1080 and HT-29 cells were 
compared. Cells were treated with different formulations containing DOX and FITC-siRNA for 1 hour and analyzed for fluorescence by flow cytometry. 
Data = mean ± SD, n = 3. **P < 0.001. DOX, doxorubicin.
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characterization of the nanoparticles  
containing sirnA and doX
In this study, we have explored a novel strategy for specifically co-
delivery of siRNA and DOX to the tumor by using DNA–DOX 
physical complex. The preparation of LPD-PEG-NGR containing 
DOX is shown in Figure 5a. Supplementary Figure S4 showed 
that the fluorescence of DOX was quenched upon its intercala-
tion into DNA, whereas the fluorescence was enhanced when the 
cationic liposomes were added. The average size of the LPD-PEG-
NGR nanoparticles containing DOX was 188 ± 29 nm and the zeta 
potential was 27.2 ± 1.0 mV. The resulting nanoparticles efficiently 
delivered DOX to the HT-1080 cells as much as the free DOX 
(Figure 5b). DOX was found in the nuclei of the cells. DOX uptake 
was further compared among different nanoparticle formulations 
by using flow cytometry. FITC-labeled siRNA was included in the 
nanoparticles for comparison. As can be seen in Figure 5d, both 
siRNA and DOX were taken up by CD13+ HT-1080 cells more 
than the CD13− HT-29 cells. However, the enhanced uptake was 
only seen with formulations targeted with NGR. Thus, peptide-
targeted LPD nanoparticles showed potential to deliver both 
siRNA and DOX to tumor cells in a target-specific manner.
uptake of doX in vivo
We studied the DOX uptake of HT-1080 tumor tissue in the 
tumor-bearing mice 4 hours after IV injection using confocal 
microscopy. As shown in Figure 6a, the LPD-PEG-NGR showed 
stronger cytosolic delivery of cy3-siRNA in the tumor tissue than 
LPD-PEG-ARA and free DOX. The distribution of DOX in the 
tumor was heterogeneous. These results indicate that the LPD-
PEG-NGR can efficiently deliver DOX to the tumor tissue and 
the intracellular delivery is targeting peptide dependent. In the 
quantitative analysis (Figure 6b), liver, kidney, heart, and spleen 
showed stronger uptake of free DOX than DOX formulated in the 
targeted nanoparticles, whereas the targeted nanoparticles showed 
stronger DOX delivery in the tumor tissue than free DOX.
tumor growth inhibition by nanoparticles  
containing sirnA and doX
Three injections of c-myc siRNA in LPD-PEG-NGR showed a 
partial inhibition of tumor growth (P < 0.05 at day 21) (Figures 5 
and 7). The control group treated with free DOX at a dose of 
0.3 mg/kg had no therapeutic effect (Figure 7). The admix-
ture of free DOX and c-myc siRNA in LPD-PEG-NGR induced 
similar tumor growth inhibition as c-myc siRNA in LPD-PEG-
NGR. A significant improvement in tumor growth inhibition was 
observed when treated with DOX and c-myc siRNA coformulated 
in LPD-PEG-NGR. The results indicate that DOX and c-myc 
siRNA co-delivered by targeted nanoparticles can synergistically 
inhibit tumor growth and enhance the therapeutic effect.
dIscussIon
c-myc gene is a key in cancer onset and maintenance in various 
human tumors. The genetic alterations of c-myc are related to 
~70,000 US cancer deaths per year. Overexpression and activa-
tion of c-myc induces various forms of cancer. However, expres-
sion of the c-myc is also essential for proliferation and regulation 
in normal mammalian cells. The aim of this study is to design a 
targeted nanoparticle formulation that can specifically deliver 
c-myc siRNA into the tumor site, downregulate c-myc expression 
in the tumor and achieve therapeutic cures. Our formulation can 
also help understand the function and mechanism of c-myc in 
tumor development.
Our results demonstrate that inhibition of c-myc protein 
expression by siRNA could induce apoptosis in HT-1080 tumors 
and significantly suppress tumor growth of HT-1080 cells in nude 











































Figure 6 tumor uptake of doX in different formulations. 
(a) Fluorescence signal of DOX in HT-1080 tumor observed by confo-
cal microscopy. (b) Tissue distribution of DOX in different formulations. 
Data = mean ± SD, n = 3. *P < 0.05 compared with free DOX. DOX, 
doxorubicin.
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Figure 7 Ht-1080 xenograft tumor growth inhibition by sirnA and 
doX in different formulations. Solid arrows indicate the intravenous 
administrations of siRNA (1.2 mg/kg) and DOX (0.3 mg/kg). Data = 
mean, n = 5–7. SD of the data points is not shown for clarity. **P < 0.01. 
DOX, doxorubicin; PBS, phosphate-buffered saline.
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in the LPD formulation, siRNA against c-myc sensitized HT-1080 
cells to DOX chemotherapy (Figure 7). The combination strategy 
may be effective to overcome the drug resistance of cancer cells 
that overexpress c-myc gene. Therefore, the new formulation may 
serve as a new strategy for cancer therapy.
There are two major issues with siRNA-based approaches in 
cancer therapy: (i) poor selectivity in delivery, i.e., inadequate 
siRNA uptake by the tumor and nonspecific siRNA uptake by nor-
mal tissues, and (ii) unfavorable pharmacokinetics, i.e., rapid clear-
ance of free siRNA in the blood. LPD-PEG-NGR is a PEGylated 
LPD containing siRNA or DOX, or both, coated with a tumor-tar-
geting peptide containing the NGR motif. We have demonstrated 
that the nanoparticles can protect siRNA from degradation in the 
systemic circulation in our previous study.9 In this study, we have 
shown that it can deliver siRNA and DOX into the tumor site, 
increase the accumulation of siRNA and DOX in the tumor tis-
sues (Figures 2 and 6), downregulate the target gene (Figure 3), 
and improve tumor growth inhibition effect (Figures 5 and 7). 
Furthermore, it has been reported that NGR motif can also target 
the tumor blood vessels.21 Our results also demonstrate that LPD-
PEG-NGR can specifically and efficiently deliver the fluorescence-
labeled siRNA into the HUVEC endothelial cells (Supplementary 
Figure S2). By using siRNA against angiogenesis, our delivery 
system could serve as a carrier to deliver therapeutic siRNA into 
tumor vascular endothelial cells and disrupt tumor vasculature. 
LPD-PEG-NGR containing therapeutic siRNA could serve as a 
novel anticancer agent for a wide variety of tumors.
In Figure 5d, NGR-targeted LPD nanoparticles deliver more 
siRNA and DOX to HT-1080 tumor cells than to HT-29 tumor 
cells. However, the nonspecific uptake of DOX (Figure 5c,d) may 
be due to the poor entrapment of DOX in the LPD nanoparticles. 
The data in Supplementary Figure S4 suggest that when the 
cationic liposomes interacted with the negatively charged DNA/
protamine complex, there was a substantial leakage of DOX from 
the nanoparticle-associated DNA. Indeed, DOX encapsulation in 
the final LPD nanoparticles was only about 20%. It implies that 
addition of cationic liposome may decrease the entrapment effi-
ciency. The positive charge of the C-3′ amine of DOX is required 
to stabilize the intercalation into DNA via charge interaction with 
the negative charge of the DNA phosphate backbone.22 Cationic 
lipid may directly compete with the DOX for interaction with 
calf thymus DNA and dislodge DOX from the DNA. However, 
the small amount of DOX entrapped in the LPD-PEG-NGR 
induced a significantly increased tumor uptake (Figure 6) in the 
HT-1080 tumor model. A significant improvement in therapeutic 
effect was also achieved by the small amount of DOX entrapped 
in the targeted nanoparticle (Figure 6). Free, unentrapped DOX 
was rapidly cleared from the blood circulation after IV admin-
istration and rarely uptaken in the tumor tissue. If the interac-
tion of DNA with cationic liposomes, but not with protamine, 
was the cause of the DOX leakage, we will attempt to modify the 
nanoparticle formulation to enhance entrapment efficacy in our 
future study.
The tumor-homing peptide (NGR) modified nanoparticle 
provides an enhancement of drug potency and may potentially be 
a therapeutic agent against drug-resistant tumors when combined 
with siRNA against drug-resistant genes such as p-glycoprotein.
MAterIAls And MetHods
Materials. DOTAP and cholesterol were purchased from Avanti Polar 
Lipids (Alabaster, AL). Protamine sulfate (fraction X from salmon) and calf 
thymus DNA (for hybridization, phenol-chloroform extracted and ethanol 
precipitated) were purchased from Sigma-Aldrich (St Louis, MO). DOX 
was purchased from IFFECT Chemphar (Hong Kong, People’s Republic of 
China). Synthetic 19-nt RNAs with 3′ dTdT overhangs on both sequences 
were purchased from Dharmacon (Lafayette, CO). For quantitative stud-
ies, cy3 was conjugated to 5′ sense sequence. 5′-cy3- and 5′-FITC-labeled 
siRNA sequence was also obtained from Dharmacon. The sequence of c-myc 
siRNA was 5′-AACGUUAGCUUCACCAACAUU-3′ and control siRNA 
with sequence 5′-AATTCTCCGAACGTGTCACGT-3′ was obtained from 
Dharmacon. DSPE-PEG-NGR (GNGRGGVRSSSRTPSDKYC), a peptide 
ligand conjugated to a PEG chain tethered to a phospholipid (Figure 1a), 
and DSPE-PEG-ARA (GARAGGVRSSSRTPSDKYC), a similar conju-
gate but containing the control peptide ARA, were supplied by Ambrilia 
Biopharma.23 These conjugates were used to modify the surface of the 
nanoparticles, as described,24 to obtain LPD-PEG-NGR and LPD-PEG-
ARA containing siRNA.
Cell culture. HT-1080 and HT-29 cells were obtained from American 
Type Culture Collection, Manassas, VA. HT-1080 cells were maintained 
in MEM Alpha Media (Gibco-BRL, Carlsbad, CA) supplemented with 
10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/ml penicillin, 
and 100 µg/ml streptomycin (Invitrogen). HT-29 cells were maintained 
in McCoy’s 5A Modified Medium (Cellgro, Manassas, VA) supplemented 
with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml strepto-
mycin (Invitrogen). To study the siRNA uptake, HT-1080 cells were chosen 
as the CD-13 receptor positive human tumor cell lines and HT-29 cells as 
receptor negative control cell lines.17
Preparation of PEGylated LPD formulations. LPD were prepared accord-
ing to the previously method with slight modifications.24 Briefly, cationic 
liposomes composed of DOTAP and cholesterol (1:1 molar ratio) were 
prepared by thin film hydration followed by membrane extrusion to 
reduce the particle size. To prepare LPD, 18 µl of protamine (2 mg/ml), 
140 µl of deionized water, and 24 µl of a mixture of siRNA and calf thymus 
DNA (2 mg/ml) were mixed and kept at room temperature for 10 minutes 
before adding 120 µl of cationic liposome (10 mmol/l). LPD stood at room 
temperature for 10 minutes before the addition of DSPE-PEG. LPD was 
then mixed with 37.8 µl of DSPE-PEG-NGR or DSPE-PEG-ARA (17 mg/
ml) and kept at 50–60 °C for 10 minutes.
Cellular uptake study. Human HT-1080 and HT-29 cells, originally 
obtained from ATCC, (1 × 105 per well) were seeded in 12-well plates 
(Corning, Corning, NY) 12 hours before experiments. Cells were treated 
with different formulations at a concentration of 250 nmol/l for 5′-cy3-
labeled siRNA or 1.5 µmol/l DOX in serum-containing medium at 37 °C 
for 4 hours. Cells were washed twice with phosphate-buffered saline (PBS), 
counterstained with DAPI and imaged using a Leica SP2 confocal micro-
scope (Leica Microsystems, Bannockburn, IL). DOX uptake of HT-1080 
and HT-29 cells was also measured by flow cytometry. Briefly, cells were 
treated with different formulations at a concentration of 1.5 µmol/l DOX 
in serum-containing medium at 37 °C for 1 hour. Cells were harvested and 
resuspended at a concentration of 1 × 106 cells/ml. Cells were washed with 
PBS and analyzed immediately by flow cytometry.
Gene silencing study. Sterile round cover slips (1 × 1 cm) were placed 
into each well in 24-well plates. HT-1080 cells (5 × 104 cells/0.5 ml/well) 
were then seeded into each well overnight. Cells were treated with differ-
ent formulations at a concentration of 250 nmol/l for c-myc siRNA in 10% 
fetal bovine serum–containing medium at 37 °C for 24 hours. Cells were 
washed three times with PBS and fixed with cold acetone/methanol 1:1 for 
10 minutes. Cells were incubated with anti-c-myc antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) at 1:50 dilution for 1 hour. After washing 
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with PBS, immunostaining was carried out by using a kit (DakoCytomation 
Envision + Dual Link System-HRP (DAB+); DakoCytomation, Carpinteria, 
CA) following the vendor’s protocol. For in vivo study, HT-1080 tumor-
bearing mice (tumor size ~1 cm2) were IV injected with siRNA in different 
formulations (1.2 mg siRNA/kg, one injection per day for 3 days). A day 
after the third injection, tumors were collected, paraffin embedded and sec-
tioned. Some sections were analyzed for TUNEL assay (see below). Sections 
of 7¼ µm thick were immunostained with primary antibodies and visualized 
by using kits from DakoCytomation. Samples were imaged by using a Nikon 
Microphot SA microscope (Nikon Instruments, Melville, NY).
Western blot analysis. Cells were lysed in lysis buffer CelLytic M Cell Lysis 
Reagent (Sigma-Aldrich) for 30 minutes on ice, and the supernatant was 
collected after centrifugation at 12,000 rpm. Cell lysates were separated on 
a 10% acrylamide gel and transferred to a PVDF membrane. Membranes 
were blocked for 1 hour in 5% skim milk and then incubated with poly-
clonal antibody against c-myc (Santa Cruz Biotechnology) overnight. 
Membranes were washed in PBST (PBS with 0.1% Tween-20) three times 
and then incubated for 1 hour with secondary antibody. Membranes were 
washed four times and then developed by an enhanced chemilumines-
cence system according to the manufacturer’s instructions (PerkinElmer, 
Waltham, MA). For in vivo study, HT-1080 tumor-bearing mice (tumor 
size ~1 cm2) were IV injected with siRNA in different formulations (1.2 mg 
siRNA/kg, one injection per day for 3 days). A day after the third injection, 
mice were killed and tumor samples were collected. Total protein (40 µg) 
isolated from the tumors was loaded on a polyacrylamide gel, electro-
phoresed, blotted as described above.
Assessment of apoptosis by TUNEL staining. Paraffin sections of HT-1080 
tumor were stained by using TACS TdT Kit (R&D Systems, Minneapolis, 
MN) according to the manufacturer’s recommendation. The apoptotic 
cells were counted in four randomly selected visual fields for each treat-
ment. The apoptotic index was calculated as the ratio of apoptotic nuclei 
to total nuclei.
Tumor uptake study. Mice with tumor size of ~1 cm2 were IV injected with 
cy3-labeled siRNA (1.2 mg/kg) or DOX (1.2 mg/kg) in different formula-
tions. After 4 hours, mice were killed and tissues were collected, fixed in 
10% formalin and embedded in paraffin. Tumor tissues were sectioned 
(7¼ µm thick) and imaged using a Leica SP2 confocal microscope.
Tissue distribution study. Mice with tumor size of ~1 cm2 were IV injected 
with FITC-labeled siRNA or DOX in different formulations (1.2 mg/kg). 
After 4 hours, mice were killed, and tissues were collected and homog-
enized in lysis buffer and incubated at room temperature for 30 min-
utes. The supernatant was collected after centrifugation at 14,000 rpm 
for 10 minutes, and 50 µl supernatant was transferred to a black 96-well 
plate (Corning). The fluorescence intensity of the sample was measured 
by a plate reader (Bioscan, Washington, DC) at excitation wavelength of 
485 nm and emission wavelength of 535 nm. siRNA and DOX concentra-
tion in each sample was calculated from a standard curve.
Tumor growth inhibition study. HT-1080 tumor-bearing mice (size 
16–25 mm2) were IV injected with different formulations containing 
siRNA (1.2 mg/kg) or DOX (0.3 mg/kg) once per day for 3 days. Tumor 
size in the treated mice was measured after treatment.
Statistical analysis. All statistical analyses were performed by Student’s 
t-test. Data were considered statistically significant when P value was <0.05.
suPPleMentArY MAterIAl
Figure S1. Ligand competitive cellular uptake assay.
Figure S2. Intracellular uptake of siRNA in HUVEC.
Figure S3. Relative mRNA level in the HT1080 cells 24 h after treat-
ment with siRNA in different formulations.
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